However, CSF1R blockade in combination with either an antibody against PD-1 or CTLA-4, except for gemcitabine, led to improved tumor regression [101], suggesting that CSF1R blockade induced reduction of TAMs and enabled response to ICB. The gene discussed is PDCD1; the disease is neoplasm.